Clinical trial
Topotecan Plus Cisplatin Versus Etoposide Plus Cisplatin In 1st Line Extensive…
NCT00320359 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00320359 |
|---|---|
| Title | Topotecan Plus Cisplatin Versus Etoposide Plus Cisplatin In 1st Line Extensive Disease Small Cell Lung Cancer |
| Official title | An Open-Label, Multicentre, Randomised, Phase III Study Comparing Topotecan/Cisplatin and Topotecan/Etoposide Versus Etoposide/Cisplatin as Treatment for Chemotherapy-naive Patients With Extensive Disease-Small Cell Lung Cancer |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lung Cancer, Small Cell |
| Intervention type | Drug |
| Interventions | Intravenous topotecan/cisplatin, Intravenous etoposide/cisplatin |
| Enrollment | 700 |
| Start date | Aug 1, 2002 |
| Primary completion | Feb 1, 2007 |
| Completion | Feb 1, 2007 |
| First posted | May 3, 2006 |
| Last update posted | Mar 1, 2017 |
| Countries | Austria, Germany |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: